Stock comparison
AbbVie
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABBV
AbbVie
Market cap
$371.72B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABBV | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 55C | 67B | IDXX |
| Benjamin Graham | 80A | 72B | ABBV |
| Philip Fisher | 53C | 67B | IDXX |
| Peter Lynch | 22F | 63C | IDXX |
| Joel Greenblatt | 33F | 75B | IDXX |
| Charlie Munger | 60C | 79B | IDXX |
| Terry Smith | 57C | 76B | IDXX |
Side-by-side metrics
| Metric | ABBV | IDXX |
|---|---|---|
| Market cap | $371.72B | $42.11B |
| P/E (TTM) | 102.6x | 39.0x |
| EV/EBIT | 21.7x | 31.6x |
| ROIC (TTM) | 10.29% | 40.66% |
| Gross margin | 73.46% | 62.05% |
| Net margin | 5.79% | 24.63% |
| Revenue CAGR 5y | 2.14% | 7.56% |
| EPS CAGR 5y | -22.23% | 10.79% |
| Debt / Equity | 2.6x | 0.7x |
| Dividend yield | 3.2% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABBV leads on
- Dividend yield3.2%vs 0.0%+100%
- Market cap$371.72Bvs $42.11B+89%
- EV/EBIT21.7xvs 31.6x+31%
- Gross margin73.46%vs 62.05%+16%
IDXX leads on
- EPS CAGR 5y10.79%vs -22.23%+149%
- Net margin24.63%vs 5.79%+76%
- ROIC (TTM)40.66%vs 10.29%+75%
- Debt / Equity0.7xvs 2.6x+74%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.